| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/22/2004 | WO2004060055A1 Wt1 transgenic animal |
| 07/22/2004 | WO2004050115A3 Combination treatment using exendin-4 and thiazolidinediones |
| 07/22/2004 | WO2004043456A8 Cholesterol absorption inhibitors for the treatment of demyelination |
| 07/22/2004 | WO2004041118A3 Therapeutic compositions for drug delivery to and through covering epithelia |
| 07/22/2004 | WO2004039313A3 Preventing desensitization of receptors |
| 07/22/2004 | WO2004037235A3 Method and composition for preventing and treating solid tumors |
| 07/22/2004 | WO2004037186A8 Prophylactic treatment methods |
| 07/22/2004 | WO2004026238A8 Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers |
| 07/22/2004 | WO2004024884A3 Syts as modifiers of the p21 pathway and methods of use |
| 07/22/2004 | WO2004021977A3 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
| 07/22/2004 | WO2004010932A3 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| 07/22/2004 | WO2004006843A3 Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
| 07/22/2004 | WO2004005529A3 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF |
| 07/22/2004 | WO2003087303A3 Tissue composites and uses thereof |
| 07/22/2004 | WO2003073916A3 Immune regulation |
| 07/22/2004 | WO2003072135A3 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| 07/22/2004 | WO2003059293A3 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators |
| 07/22/2004 | WO2003059148A3 Gene expression profiles in stomach cancer |
| 07/22/2004 | WO2003053215A3 Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
| 07/22/2004 | WO2003014299A3 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 07/22/2004 | WO2003006002A9 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 07/22/2004 | WO2002102232A3 A novel signaling pathway for the production of inflammatory pain and neuropathy |
| 07/22/2004 | WO2002101076A3 Methods for targeted expression of therapeutic nucleic acid |
| 07/22/2004 | WO2002099048A3 LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 07/22/2004 | WO2002088090A3 Pyrazole derived kinase inhibitors |
| 07/22/2004 | US20040143022 Amine compounds and inhibiting neurotransmitter reuptake |
| 07/22/2004 | US20040143017 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors |
| 07/22/2004 | US20040143015 Mixture of antidiabetic agents and carrier; prevent, delay metabolism disorders |
| 07/22/2004 | US20040143014 Therapeutic use of alpha-2-delta ligands |
| 07/22/2004 | US20040143010 Synergistic mixture with phosphodiesterase inhibitor; control concentration of cyclic guanosine monophosphate in penis |
| 07/22/2004 | US20040143003 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 07/22/2004 | US20040142993 Viricides |
| 07/22/2004 | US20040142989 Viricides |
| 07/22/2004 | US20040142972 Sleep disorders; side effect reduction ; antihistamine antagonist |
| 07/22/2004 | US20040142958 Combination therapy for the treatment of pain |
| 07/22/2004 | US20040142944 Compositions for nasal application |
| 07/22/2004 | US20040142938 for treating diabetes and related diseases |
| 07/22/2004 | US20040142919 Benzazepinone alpha vintegrin receptor antagonists |
| 07/22/2004 | US20040142886 use of vascular endothelial growth factor to enhance smooth muscle cell proliferation and to treat diseases associated with reduced smooth muscle cell proliferation |
| 07/22/2004 | US20040142871 Osteoporosis treatment |
| 07/22/2004 | US20040142863 modified aggrecanases, nucleotides encoding such enzymes, and processes for producing these enzymes with improved stability; treatment of osteoarthritis |
| 07/22/2004 | US20040142852 vitamin; a metal salt that provides metal ions in vivo; and insulin or a growth hormone |
| 07/22/2004 | US20040142465 Injectable hyaluronic acid derivative with pharmaceuticals/cells |
| 07/22/2004 | US20040142431 Nucleotide sequences comprising restriction fragment length polymorphisms coding polypeptide with antiproliferative, antiviral and antiparasitic effects |
| 07/22/2004 | US20040142421 Pacemake ion channel proteins and uses thereof |
| 07/22/2004 | US20040142394 Method for diagnosing a tumor in a patient determining the concentration of PIBF |
| 07/22/2004 | US20040142391 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with RAGE |
| 07/22/2004 | US20040142388 Method for detecting chronic dementia diseases, and corresponding VGF peptides and detection reagents |
| 07/22/2004 | US20040142354 used to diagnose and/or treat a wide variety of liver and other disorders (cancer) and tracing hepatocyte lineage; genetic engineering |
| 07/22/2004 | US20040142342 Antibodies to non-functional P2X7 receptor diagnosis and treatment of cancers and other conditions |
| 07/22/2004 | US20040142036 unit aliquot dose of a pharmaceutical electricstatically deposited on a porous, permeable or semi-permeable ingestible membrane; including two or more active pharmaceuticals segregated from one another in a single delivery package. |
| 07/22/2004 | US20040142027 vehicle comprising; a modified unsaturated oil and, optionally, a non-oxidizable oil; immediately after manufacture, composition can be administered such that the bioactive agents are released to the host on a predictable sustained basis. |
| 07/22/2004 | US20040142018 Regulator for amount of body fat |
| 07/22/2004 | US20040142005 treating a cardiovascular disease, especially preventing restenosis in a blood vessel which may occur following a cardiovascular procedure, |
| 07/22/2004 | US20040141981 administering biological conjugates comprising chlorotoxin sensitive cytoplasmic proteins, used for the screening and prophylaxis of cancer |
| 07/22/2004 | US20040141973 IPG antagonists for the treatment of conditions involving mast cells, basophils and eosinophils |
| 07/22/2004 | US20040141967 Methods and compositions for treating macrophage-mediated diseases |
| 07/22/2004 | US20040141950 Immunostimulatory combinations |
| 07/22/2004 | US20040141949 Treatment of mucositis |
| 07/22/2004 | US20040141924 Administering an antiasthmatic-effective amount of a MEK inhibitor to a patient in need of treatment, or to a patient suspected of developing asthma and in need of prophylactic treatment |
| 07/22/2004 | US20040141912 Administering medicinally-useful agent which is phospholipid scramblase (PLS)-dependent transported compound to cells, thereby causing selective transport of agent into cells |
| 07/22/2004 | CA2552261A1 Cardioprotective delta opioid receptor agonists and methods of using same |
| 07/22/2004 | CA2512558A1 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells |
| 07/22/2004 | CA2512001A1 Complexes of protein crystals and ionic polymers |
| 07/22/2004 | CA2511838A1 Uses of mammalian cytokine; related reagents |
| 07/22/2004 | CA2511823A1 Combination therapy with co-stimulatory factors |
| 07/22/2004 | CA2511817A1 Novel compositions and methods in cancer |
| 07/22/2004 | CA2511816A1 Methods and compositions for the diagnosis, prognosis, and treatment of cancer |
| 07/22/2004 | CA2511538A1 Immunostimulatory combinations |
| 07/22/2004 | CA2510903A1 Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 07/22/2004 | CA2510584A1 Combination of reboxetine and a cyclooxygenase-2 inhibitor |
| 07/22/2004 | CA2509731A1 Treatment of hiv infection through combined administration of tipranavir and capravirine |
| 07/22/2004 | CA2508884A1 A method for the treatment, prevention, or inhibition of a cns disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| 07/21/2004 | EP1439190A1 Growth differentiation factor-5 |
| 07/21/2004 | EP1438971A1 Immunopotentiators in thermotherapy for cancer |
| 07/21/2004 | EP1438968A1 Topical compositions containing at least one polypeptide hydrolase with an amidasic activity and /or compounds capable of modulating this activity |
| 07/21/2004 | EP1438967A2 Pharmaceutical compositions of fibrinolytic agent |
| 07/21/2004 | EP1438965A1 Use of extracts from Hoodia gordonii and Hoodia lugardii for the preparation of a medicament for use in the suppression of appetite |
| 07/21/2004 | EP1438962A1 DRUGS COMPRISING COMBINATION OF TRIAZASPIRO 5,5 U NDECANE DERIVATIVE WITH CYTOCHROME P450 ISOZYME 3A4 INHIBITOR AND/OR P−GLYCOPROTEIN INHIBITOR |
| 07/21/2004 | EP1438431A2 Methods for diagnosing and treating heart disease |
| 07/21/2004 | EP1438418A2 Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| 07/21/2004 | EP1438407A1 Obesity related genes expressed at least in the hypotalamus, liver or pancreas |
| 07/21/2004 | EP1438404A2 Inhibition of specific histone deacetylase isoforms |
| 07/21/2004 | EP1438389A2 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer |
| 07/21/2004 | EP1438388A1 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer |
| 07/21/2004 | EP1438386A2 Transmembrane protein differentially expressed in cancer |
| 07/21/2004 | EP1438334A2 Identification of specific tumor antigens by means of the selection of cdna libraries with sera |
| 07/21/2004 | EP1438333A2 Anti-fusion assay |
| 07/21/2004 | EP1438310A1 Beta-carbolin derivatives as ptp-inhibitors |
| 07/21/2004 | EP1438297A1 Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina |
| 07/21/2004 | EP1438292A1 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 07/21/2004 | EP1438074A2 Adjuvant compositions |
| 07/21/2004 | EP1438071A1 Therapies for treating respiratory diseases |
| 07/21/2004 | EP1438070A1 Treating vascular disease by inhibiting toll-like receptor-4 |
| 07/21/2004 | EP1438069A1 Enzyme inhibitors for inactivating allergens |
| 07/21/2004 | EP1438063A1 Modulation of physiological processes and agents useful for same |
| 07/21/2004 | EP1438062A2 Methods and compositions for treating dermal lesions |
| 07/21/2004 | EP1438061A2 Copolymers for suppression of autoimmune diseases, and methods of use |
| 07/21/2004 | EP1438060A2 Prevention and treatment of restenosis by local administration of drug |
| 07/21/2004 | EP1438049A2 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage |